Seeking Alpha

Plavix, which has brought Bristol-Myers Squibb (BMY) $42.8B over 15 years, loses its patent...

Plavix, which has brought Bristol-Myers Squibb (BMY) $42.8B over 15 years, loses its patent protection today. In total, 19 drugs are set to relinquish such protection in 2012 - dubbed the year of "pharmageddon" - costing the industry $38.5B. BMY is now pinning its hopes on the yet-to-be-approved blood thinner Eliquis to make up for Plavix.
From other sites
Comments (1)
  • QC
    , contributor
    Comments (28) | Send Message
     
    I own BMY. I also take Plavix. Although a wonderful medicine- it is very expensive, I am glad it will become generic. Bristol-Myers Squibb has made fortune on Plavix.
    17 May 2012, 12:07 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs